Buchumschlag

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	María Hernández‐Pérez, Daniel Riado, Eva Pena, Carmen Méndez, Fernando Pinedo, Paloma Ramos, Pilar Castillo, Miriam Romero, Conrado Fernández‐Rodríguez, Antonio Olveira
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?
von: John E. Eaton, et al.
Veröffentlicht: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
von: Mohamed I. Elsaid, et al.
Veröffentlicht: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
von: Mohamad Jamalinia, et al.
Veröffentlicht: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
von: Lukas Burghart, et al.
Veröffentlicht: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
von: Rocio Enriquez, et al.
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
von: Guilherme Grossi Lopes Cançado
Veröffentlicht: (2024)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
von: Angelo Armandi, et al.
Veröffentlicht: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
von: Nipun Verma, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
von: Manya Prasad, et al.
Veröffentlicht: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
von: Ayesha Shah, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
von: Samer Gawrieh, et al.
Veröffentlicht: (2024)

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
von: Palak J. Trivedi, et al.
Veröffentlicht: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
von: Amanda Ricciuto, et al.
Veröffentlicht: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
von: Antonio De Vincentis, et al.
Veröffentlicht: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
von: Lukas Hartl, et al.
Veröffentlicht: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
von: David Uihwan Lee, et al.
Veröffentlicht: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
von: Mar Riveiro‐Barciela, et al.
Veröffentlicht: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
von: Sung Won Chung, et al.
Veröffentlicht: (2024)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
von: C. Stephens
Veröffentlicht: (2024)

Editorial: The future of managing drug induced liver injury
von: Amanda Nicoll
Veröffentlicht: (2024)

Review article: Oesophageal disorders in chronic liver disease
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
von: Shusuke Kumazaki, et al.
Veröffentlicht: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
von: Yaomin Wang, et al.
Veröffentlicht: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
von: Deepak Joshi, et al.
Veröffentlicht: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
von: Zhuo Li, et al.
Veröffentlicht: (2024)